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Abstract
Background:  Head and neck cancer including oral cancer is considered to develop by
accumulated genetic alterations and the major pathway is cancerization from lesions such as
intraepithelial dysplasia in oral leukoplakia and erythroplakia. The relationship of proliferation
markers with the grading of dysplasia is uncertain. The involvement of EBV in oral carcinogenesis
is not fully understood.
Aim: The present study was designed to investigate the role of EBV and DNA Topoisomerase II∝
(DNA-Topo II∝) during oral carcinogenesis and to examine the prognostic significance of these
protein expressions in OSCCs.
Methods: Using specific antibodies for EBV and DNA-Topo II∝, we examined protein expressions
in archival lesion tissues from 16 patients with oral epithelial dysplasia, 22 oral squamous cell
carcinoma and 20 normal oral mucosa by immunohistochemistry. Clinical information was obtained
through the computerized retrospective database from the tumor registry.
Results: DNA-Topo II∝ was expressed in all examined specimens. Analysis of Variance ANOVA
revealed highly significant difference (P < 0.01) in young aged labial tissues and significant (P ≤ 0.05)
in gingival and not significant (P > 0.05) in inferior surface of tongue and in hard palatal tissues.
Significant differences were observed between OEDs and NSE (P < 0.001) and SCCs and controls
(P < 0.001), also, significant differences could be observed between SCCs and OEDs. DNA-Topo
II∝ expression was significantly higher in tumors of low differentiation versus tumors of moderate
and high differentiation (P < 0.001), DNA-Topo II∝ expression was correlated with age, tumor size,
tumor stage, node metastasis and tumor differentiation, but not with gender and tumor site. None
of normal squamous epithelium (NSE) expressed EBV. Heterogenous reactivity for EBV was
observed through the series of dysplasia and squamous cell carcinoma. Its expression increased
progressively with lymph node metastasis and low tumor differentiation, but no significant
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association could be observed with other clinicopathological parameters. EBV protein expression
was increased with elevated Topo II-∝ LI in OEDs and OSCCs. A tendency to positive correlation
between EBV and Topo II∝ expression was observed in OEDs but not in OSCCs.
Conclusion: EBV and DNA Topo II-αLI expression are possible indicators in oral carcinogenesis
and may be valuable diagnostic and prognostic indices in oral carcinoma.
Background
Oral carcinogenesis is generally considered to be a molec-
ular and histologic multistep process that includes activa-
tion of oncogenes, inactivation of tumor suppressor genes
and involvement of viral genes [1,2]. The histologic fea-
tures are predominantly caused by alteration of cell kinet-
ics in the proliferative pool of the epithelium, expressed as
increased growth fraction and cell division rate. This alter-
ation determines the transformation of normal oral epi-
thelium into a malignant tumor [3]. According to this
hypothesis, the steps of the transformation from normal
epithelium to carcinoma are low grade and high-grade
oral intraepithelial neoplasias (OINs). These dysplastic
alterations are considered to be the precursory steps of the
invasive squamous cell carcinoma [4].
The presence and severity of dysplasia are often regarded
as an indicator of the risk status of a precancerous lesion
[5]. Severe dysplasia indicates a very high risk of the sub-
sequent development of cancer [6]. However, Lind
reported that the grading of dysplasia was not propor-
tional to the risk of independent transformation [7].
The question arises as to what can replace the routine his-
tological reporting considered as the gold standard for
assessing the risk of a potentially malignant oral lesion
[3]. The search for alterations in molecular and genetic
characteristics has so far not yielded predictive risk mark-
ers to assess the malignant potential of oral dysplastic
lesions [8]. Among an array of genetic aberrations
reported both in oral precancer and in squamous cell car-
cinoma (e.g. p35, p16/MTS1, and cyclin D), none has
been shown to be sufficient or necessary for transforma-
tion of oral keratinocytes. Lack of clearly defined gate-
keeping genes for this site has hampered progress in iden-
tifying early biomarkers of progression. Of the available
biomarkers [9], one would expect those identifying
genomic status and cell proliferation to correspond
closely to the cellular and tissue changes observed in dys-
plasia [10].
Analysis of the cell kinetics of cancer cells in situ for exam-
ple, by mitotic counts, DNA analysis, or Ki-67 antigen
expression is used increasingly to evaluate the prognosis
and/or biological behavior of various human malignan-
cies DNA Topoisomerase II (Topo II) is thought to be one
of these cell cycle related proteins, and Topoisomerase IIα
(Topo IIα), one of its isoforms, has been shown to play an
important role in the cell cycle through catalyzing the top-
ological isomerisation of DNA by passing one strand of
DNA through a reversible break in a second DNA strand
[11]. Dysregulation or qualitative alterations of Topo IIα
expression in the cell cycle are being reported in both nor-
mal tissues and various human neoplasms' [12-14]. The
sensitivity or resistance of a malignant cell to several anti-
tumour drugs known as "Topo II poisons" is quantita-
tively dependent on the cellular content of Topo II [15].
Although considerable insight has been gained into
Epstein Barr virus (EBV) as an important etiologic factor
in a variety of diseases, benign and malignant disorders
[16] e.g. extra-hepatic biliary atresia [17], infectious
mononucleosis [18], Burkitt' s lymphoma [19], oral hairy
leukoplakia [20], salivary gland tumors [21] and nasopha-
ryngeal carcinoma (NPC) [22], virtually little is known
about the possible role of viruses and their interactions
with genes [23]. EBV is a herpes virus; it is clearly associ-
ated with Burkitt' s lymphoma [19] and anaplastic carci-
noma [24] and the oncogenicity is not in doubt. However,
EBV-DNA antigens have not been demonstrated in carci-
nomas from other sites of the head & neck or cell lines
[24-27]. This association has proved to be consistent
regardless of the degree of differentiation of the neoplasm
and extent of lymphocytic infiltration [28]. EBV can be
considered a possible candidate for participation in the
process of carcinogenesis for several reasons. Firstly, oral
squamous epithelium can potentially support EBV per-
sistence as exemplified by oral hairy leukoplakia. Sec-
ondly, nasopharyngeal carcinoma, also a squamous cell
carcinoma, harbors EBV DNA and viral transcripts [29].
However, only limited information is available on EBV
expression in head and neck including oral cancer.
In the present study, we examined immunohistochemi-
cally the expression of EBV and DNA Topoisomerase
(DNA-Topo) II∝ in normal keratinized & non keratinized
oral mucosa and also, to compare their expressions in oral
epithelial dysplasias (OEDs) and oral squamous cell car-
cinomas (OSCC) with the normal oral mucosa to deter-
mine whether their expressions have the potentiality to be
used as a biomarkers in the study and management of pre-
malignant and malignant epithelial lesions.Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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Methods
Paraffin-embedded, formalin-fixed tissue blocks were
retrieved from archival files of Oral pathology & general
pathology Departments, Faculty of Dentistry & Medicine,
Mansoura and Minia Universities between November
1997 and April 2006. Thirty eight patients (12 women
and 26 men) treated for primary SCC of the oral cavity
and premalignant oral lesions were selected for the study.
None of patients received chemotherapy or radiotherapy
before operation. All diagnoses were revised, and the
lesions were classified according to the World Health
Organization (1997) [30]. Histologic typing of the cancer
and precancer of the oral mucosa. They included 16 oral
epithelial dysplasia (OED) {7 mild dysphasia with the age
range of 20–64 years, 5 moderate dysplasia with the age
range of 30–52 years, 4 severe dysplasia with the age of
22–71 years} and 22 oral squamous cell carcinomas
(OSCCs) with the age of 24–71 years. Specimens of OED
were obtained from the buccal mucosa (11 cases) and
floor of the mouth (5 cases) while 22 specimens of OSCC
were obtained, five from the tongue, 3 from the gingiva, 2
from the floor of the mouth, 9 from the buccal mucosa
and 3 from the hard palate. Twenty-two oral squamous
cell carcinoma cases were classified according to the TNM
classification of the International Union Against Cancer
(UICC, 2002) [31]. 22 in T categories, 8 patients were in
T1, 10 in T2, 4 in T3. In N category, 9 patients were in N0,
11 in N1 and 2 in N2. Of the 22 SCCs, 5 were Stage I, 4
were Stage II, 11 were Stage III, and 2 were Stage IV. His-
topathologically, 10 were well differentiated SCC, 8 were
moderate differentiated SCC, 4 were poorly differentiated
SCC corresponding to Grades I, II, and III respectively.
Twenty tissue specimens of different normal oral tissues
(gingiva, hard palate, lip and inferior surface of tongue as
specialized mucosa) were used as control. The chosen
specimens were retrieved from Oral surgery Department,
Faculty of Dentistry, Mansoura and Minia Universities.
The specimens were classified according to their different
locations and ages. The specimens are divided according
to the age into two groups: first group from 20 to 40 years,
early and late adolescence. The second group from 40 to
75 years.
I-Clinical study
The clinical data were collected retrospectively through
the computerized retrospective database from the lesion
registry, regarding age, sex, site, tumor size and lymph
node metastasis.
II-Histological study
5 μm thick sections were prepared for (a) routine haema-
toxylin and eosin stain for histological examinations and
(b) on positively charged glass slides (Optiplus) Biogenex,
San Ramon, California, USA., for immunostaining proce-
dures.
III-Immunohistochemical study
Two sections were obtained from each case, one for posi-
tive test slide and the other for negative control (by omit-
ting the primary antibody and non-immune serum is used
instead of primary antibodies). Immunohistochemical
staining was carried out using labeled streptavidin-biotin
peroxidase complex technique Enzinger FM and Weiss SW
1988[32] (DAKO LSAB +Kit, HRP) DAKO-Dakopatts,
Glostrup, Denmark(code no.k0679). After dewaxing and
rehydration, sections were incubated for 5 minutes at
37°C in 0.05% protease type XXIV Sigma in phosphate
buffered saline (PBS). This was followed by endogenous
peroxidase block using 0.3% menthanolic H2O2. Sec-
tions were then washed in PBS, and incubated for 5 min-
utes in 1% Bovine Serum Albumin (BSA) to reduce non
specific binding. The monoclonal antibodies for EBV CS1-
4 (Dakopatts, diluted at 1:50) that recognizes EBV-
encoded LMP1 and mouse anti-human Topoisomerase II
α protein (DAKO, clone: Ki-S1, isotype: IgG2a) were used.
The bottle contains 1 ml of Topo II α antibody provided
in liquid form as purified IgG diluted in 0.05 M Tris/HCL,
15 mM NaN, pH 7.2, 1% bovine serum albumin (BSA).
(Bottle no. 2) was applied to 1:80 dilutions in 1% BSA in
PBS. After overnight incubation at 4°C, sections were
washed and treated with anti-rabbit, anti-mouse and anti-
goat Ig in phosphate buffered saline (PBS) for 30 minutes
at room temperature, then followed by streptavidin per-
oxidase conjugate 1:300 at 37°c for 20 min. Sections were
then washed in PBS, visualized with diamino-benzidene
H2O2 (DAB) and counterstained with Mayer's hematoxy-
line. Positive and negative controls were included. For
negative control slide, one vial (3 ml) of non-immune
serum or immunoglobulins in PSA with 0.09% sodium
azide was used.
Immunohistochemical evaluation
The immunoreactivity of each specimen was evaluated by
Light microscope to assess the intensity of EBV expression,
graded according to a 5-grade scale, and the labeling index
(LI) of DNA-Topo II∝. The percentage of EBV positive
tumor cells showing nuclear and cytoplasmic staining was
determined by counting a total of 2000 Cells in 10 ran-
domly selected fields of each section examined at 400
magnifications. EBV expression was then classified as
grade 0 (negative expression); grade 1 (low expression),
1–25% of tumor cells positive; grade 2 (intermediate
expression), 26–50% positive; grade 3 (high expression),
51–75% positive; or grade 4 (high expression), 76% or
more positive.
To evaluate the DNA-Topo II ∝ LI, cell nuclei showing
intense homogeneous brown color or granular stainingDiagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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were counted as positive in a similar manner as described
for EBV expression. The LI was defined by the percentage
of positively stained cell nuclei and the intensity was
expressed as 1+ to 4+.
Statistical analysis
It was performed using SPPS computer program v.11.0
Full. One-way ANOVA (analysis of variance) test, Inde-
pendent t-test, Spearman's rank correlation coefficient
were used for statistical analysis. Bonferroni test was used
for post hoc test. A p value less than 0.05 was regarded as
statistically significant.
Results
EBV expression and Topo Π- α LI in different normal oral 
tissues
In normal squamous epithelium (NSE), EBV expression
was negative, and Topo II∝ LI was low (5.4%). Topo II-∝
was mainly observed in the basal and parabasal cell layers
(Fig 1, 2) ranging from 1.9% to 9.7% with a mean of
5.4%.
The results of the Analysis of variance (ANOVA) which
was used to test Topo II-α LI in young aged groups of gin-
gival, labial, hard palate, inferior surface of tongue tissue
were listed in (Table 1). These results revealed highly sig-
nificant difference between young aged labial tissues ver-
sus old aged groups (P < 0.01), significant (P ≤ 0.05) in
gingival tissues and not significant (P > 0.05) in hard pal-
ate and inferior surface of tongue tissues.
EBV expression and Topo ∏-∝ LI in oral epithelial 
dysplasia
In oral epithelial dysplasia, ten out of the sixteen cases
(62.5%) were immunoreactive for EBV. Four cases (25%)
showed strong (+++) reaction, Four cases (25%) were
moderate (++) and two (12.5%) were mild (+), the posi-
tive immunosignals appeared as dark golden brown, focal
or diffuse staining within the cytoplasm and/or nucleus
corresponding to grades 1–4 in some dysplastic cells. The
reaction indicating the existence of EBV was detected in
the positive cases with variable degrees of intensity and
distribution. In mild dysplasia, strong positively stained
cells were concentrated in the prickle cell layer of the sur-
face epithelium while the basal cells were weakly stained
(Fig. 3). In some cases of moderate dysplasia, immunohis-
tochemically detectable EBV was confined to the nucleus
(Fig. 4). Few cases of severe epithelial dysplasia exhibited
both nuclear and cytoplasmic reaction (total cell reactiv-
ity).
The Topo II-∝ expression was detected in all cases studied.
The staining was usually uniform over nuclei or granular,
though some variations in staining intensity and staining
pattern were observed (Fig. 5). The staining was observed
in basal and parabasal cell layers.
Table 2 shows that the highest mean of EBV and Topo II-
α was detected in severe epithelial dysplasia (48.75 ±
33.51, 17.98 ± 1.51% respectively). A highly significant
difference between this dysplasia and control was
observed (t = -7.193,-10.78 respectively). On the other
hand, the lowest mean of EBV and Topo II-α was found in
mild epithelial dysplasia (13.43 ± 13.24, 12.27 ± 2.17%
respectively). Statistical analysis demonstrated significant
difference between this epithelial dysplasia change and its
control (t = -4.714, -7.136 respectively). Moreover, the
overall mean of EBV and Topo II-α of oral epithelial dys-
plasia (25.56 ± 25.38, 14.08 ± 2.99% respectively) was
Strong Topo IIα positivity is seen mainly in basal cells with  scattered distribution in human lip of old age group (× 250) Figure 1
Strong Topo IIα positivity is seen mainly in basal cells 
with scattered distribution in human lip of old age 
group (× 250).
Strong Topo IIα positivity is seen in human gingiva of young  age group (× 250) Figure 2
Strong Topo IIα positivity is seen in human gingiva of 
young age group (× 250).Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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significantly higher compared with control (t = -4.521, -
10.056 respectively).
EBV expression and Topo II-∝ ILI in oral squamous cell 
carcinoma
Eighteen out of the twenty-two cases (81.8%) of OSCC
showed immunopositivity for EBV. Among these eighteen
cases, ten cases showed strong (+++) reaction, while the
remaining eight cases revealed weak (+) to moderate
(+++) reaction.
The strong positively stained cells were concentrated in
the central malignant cells while peripheral cells of epi-
thelial pearls and islands were weakly stained. Immunore-
active EBV was detectable within the keratinized cells (Fig.
6). A positive cytoplasmic reaction was noted in seven
cases while the other eleven cases demonstrated both
nuclear and cytoplasmic reaction. The expression rate was
36.09% in well-differentiated SCC, 41.15% in moderate-
differentiated SCC and 57.33% in poorly differentiated
SCC (Table 2).
Topo II-∝ staining was seen as a granular or distinct, dif-
fuse nuclear pattern in basal and suprabasal cell layers
(Fig. 7, 8 &9). Topo II-∝ expression was detected in all
studied cases and the Topo ∏-∝ LI was 22.40% in well-dif-
ferentiated SCC, 28.54% in moderate-differentiated SCC
and 39.00% in poorly differentiated SCC (Table 3).
Table 1: showed mean of Topo II-α positive cell in Lip, Gingiva, Tongue and Hard palate in Young and Old aged group of Human 
different tissue.
Mean ± SE
Statistical Profile Lip(a) Gingiva(b)'
Tongue (c)
Inferior S. of Hard palate (c)
Young aged group 7.68 ± 0.31 8.59 ± 1.05 5.00 ± 2.12 5.00 ± 0.71
Old aged group 2.35 ± 0.64 4.63 ± 0.91 2.85 ± 0.07 4.60 ± 1.08
F value 7.350 0.097 2.4E+17 o.771
P value 0.002 0.01 1.000 1.000
Significant A = *** b = ** C = * c = *
(a) = *** P < 0.01 highly significant; (b) = ** P ≤ 0.05 significant; (c) = * P > 0.05 NS = Not significant.
Mild dysplasia shows existence of EBV in the prickle cells(×  400) Figure 3
Mild dysplasia shows existence of EBV in the prickle 
cells(× 400).
Moderate EBV positivity in moderate epithelial dysplasia (×  400) Figure 4
Moderate EBV positivity in moderate epithelial dys-
plasia (× 400).Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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Relationship between EBV and Topo II-∝ immunostaining 
and Clinicopathologic Characteristics in OSCC
Expression of EBV and DNA-Topo II∝ were evaluated with
respect to various prognostic factors including tumor size
(T), lymph node status (N), and stage. As almost all of
cancerous lesions showed high expression of grades 3 and
4 in EBV, 2+ and 3+ in DNA-Topo II∝ LI, distributions of
intensity of their expression were examined for T, N, M
categories and stage. Consequently, the intensity
increased as T, N, M and stage advanced (Table 3). It was
observed that patients with higher incidence of lymph
node metastasis had high both Topo II-∝ LI and EBV
expression. The significant correlation between the pres-
ence of lymph nodes metastasis and both Topo II-∝ LI
and EBV was noted (Spearman's correlation coefficients
method r = 0.635; P = 0.002, r = 0.541; P = 0.009 respec-
tively). Furthermore, the one way analysis of variances
method (ANOVA) showed significant differences between
(N-) and (N+) groups (F= 17.54, 4.88 respectively).
Topo II-∝ L indices and EBV expression were compared to
tumor status. Analysis of variance showed that there were
significant differences among the groups for Topo II-∝ LI
(F = 5.262). Significant differences were demonstrated
between (T1) and both (T2) & (T3) groups. Also Topo II-∝
L indices correlated significantly with T status of tumor (r
= 0.445; P = 0.038). However, no Significant correlation
was observed between EBV and T status of tumor (r =
0.290; P = 0.191).
The highest Topo II-∝ LI and EBV were found in stage IV
stage case. This case diagnosed histologically as poorly dif-
ferentiated squamous cell carcinoma. The lowest Topo II-
∝ LI was found in two cases, one case was in stage I and
the other in stage III, however, both were diagnosed as
well differentiated SCC. Both cases had low EBV.
Comparison of means of Topo II-∝ LI by analysis of vari-
ance (ANOVA) showed significant difference among the
groups (F = 11.10). It was found that a significant differ-
ence could be noted between stage I and stage IV groups
(Bonferroni test at significance level 0.05). Moreover, the
Spearman's correlation coefficients method showed a sig-
nificant correlation between the clinical staging of tumors
and both Topo II-∝ Indices and EBV (r = 0.630; P = 0.002
r = 0.590; P = 0.004 respectively).
Indeed, the analysis by ANOVA test did not provide us
with statistical differences between expression of EBV and
both of tumor site and age in OEDs and OSCCs. However,
there was a significant difference between male and
female in relation to EBV in OSCCs (F = 8.566) in which
EBV showed high expression in male. While, there was a
Moderate to intense EBV positivity in keratinized cells and  central malignant cells in well to moderate differentiated  SCC (× 400) Figure 5
Moderate to intense EBV positivity in keratinized cells and 
central malignant cells in well to moderate differentiated 
SCC (× 400).
Table 2: Expression of EBV and Topo II∝ in the normal oral tissues, oral epithelial dysplasia and oral squamous cell carcinomas
HISTOLOGY Number of cases EBV expression(%)(a) P-value Topo II-∝ LI (%)(b) P-value
NSE 20 0.000 ± 0.000 d 5.35 ± 2.22 c
OED 16 25.6 ± 25.38 14.08 ± 2.99
Mild 7 13.43 ± 13.24 NS 12.27 ± 2.17 NS
Moderate 5 24.00 ± 22.62 13.50 ± 1.86
Severe 4 48.75 ± 17.98 ± 1.51
OSCC 22 41.79 ± 29.31 27.56 ± 7.49
W-scc 10 36.09 ± 22.37 22.40 ± 3.19
M-scc 8 41.15 ± 33.18 NS 28.54 ± 4.84 e
P-scc 4 57.33 ± 38.91 39.00 ± 6.45
NSE, normal squamous epithelium; OED, OraLepithelial dysplasia; OSCC, oral squamous cell carcinoma; NS, not significant.
a mean ± standered deviation of EBV
b mean ± standered deviation of Topo II-α LI.
c NSE vs. OED P < 0.001;NSE vs. SCC, P < 0.001; OED vs. SCC, P = 0.083.
dNSE vs. OED P < 0.001;NSE vs. SCC, P < 0.001; OED vs. SCC, P < 0.001.
eW-SCC vs. M-SCC, P = 0.008; W-SCC 1 vs.P-SCC, P = 0.001; W-SCC vs. M-SCC +P-SCC, P < 0.001.Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
Page 7 of 13
(page number not for citation purposes)
significant difference between young and old age in rela-
tion to DNA-Topo IIα LI in OSCCs (F = 18.099) in which
DNA-Topo IIα LI showed high expression in young age.
Furthermore, no significant correlation between DNA-
Topo IIα LI and both of tumor site and gender in OEDs
and OSCCs.
Correlations between expression of EBV and Topo ∏-∝
When correlation between EBV and Topo ∏-∝ was evalu-
ated in OSCC and OED. There was a significant correla-
tion between them (r = 0.491; P = 0.054) observed in
OEDs not in OSCCs (r = 0.081; P = .720).
Discussion
It is well established that oral carcinogenesis derives from
progression of preinvasive neoplastic lesions that are char-
acterized by grade specific morphological alterations [33].
Viruses have been implicated in malignant neoplasia of
squamous epithelia so it is conceivable that they might
contribute aetiologically in some cases of oral carcinoma
[1].
Although overexpression of EBV is considered to contrib-
ute to oral carcinogenesis, there is few literatures support-
ing this hypothesis [34,35] and several reports described
the up-regulation of EBV expression in dysplasia and car-
cinoma of the head and neck cancer [34,36]. Therefore,
the present study was designed to investigate the immu-
nohistochemical expression of EBV in the 38 cases of oral
Moderate Topo IIα positivity is observed mainly in dysplastic  cells of severe epithelial dysplasia (× 400) Figure 6
Moderate Topo IIα positivity is observed mainly in 
dysplastic cells of severe epithelial dysplasia (× 400).
Moderate Topo IIα positivity is seen in moderately differenti- ated SCC (× 100) Figure 7
Moderate Topo IIα positivity is seen in moderately 
differentiated SCC (× 100).
Strong Topo IIα positivity is seen in poorly differentiated  SCC (× 250) Figure 8
Strong Topo IIα positivity is seen in poorly differenti-
ated SCC (× 250).
Higher magnification appearance of Topo IIα immunoreac- tive cells Figure 9
Higher magnification appearance of Topo IIα immu-
noreactive cells. Reaction is granular in most cells (× 400).Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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epithelial dysplasia and oral squamous cell carcinoma
and thereby to elucidate the involvement of EBV in oral
carcinogenesis. In the present study, pattern of EBV
immunostaining in the normal control sections revealed
negative results. This coincides with the results of Talacko
et al [37] and Shimakage et al [38] who found no detect-
able EBV DNA in oral mucosa of normal individuals using
in situ hybridization technique. They suggested that EBV
replicates upon entry into the oral terminally differenti-
ated keratinocytes rather than remaining latent.
Our study showed that 10 out 16 cases (62.5%) of epithe-
lial dysplasia were positive for anti-EBV antibody. This is
in agreement with Cruz and co-workers [36] who reported
the presence of EBV in 77.8% of premalignant lesions. In
contrast, Naher et al [39] and Horiuchi et al [40] found
that EBV genome was detected in 8.6% and 5.3% of their
studied oral leukoplakia cases respectively.
An interesting finding was noted in the present study. The
EBV genome was detected in the middle and upper layers
of squamous epithelium more than in the basal cell layer.
This result agrees with Greenspan [20] and Sandvei [41]
who demonstrated the presence of EBV receptors in the
prickle layer of normal oral epithelium and oral hairy leu-
koplakia.
In the current study, 18 out of the 22 (81.8%) examined
squamous cell carcinomas were positive for anti-EBV anti-
body. This is in agreement with Mao and Smith [16] and
Horiuchi et al [40] who showed that 35% and 33.3% of
their examined squamous cell carcinoma cases respec-
tively were infected with EBV. They stated that the posi-
tively rate was higher in malignant lesions than in benign
ones and agreed that EBV had a role in carcinogenesis;
however, it may exist in cancer cells as a passenger. A
higher percentage was noticed by Van Rensburg [34], Cruz
and Co-workers [36]. They observed EBV in 100% of the
oral squamous cell carcinomas, reflecting difference in
analytical methods as they used PCR which is a highly
sensitive technique.
Contradictory to our results, Talacko et al [37] using
insitu-hybridization demonstrated that EBV DNA was not
present in the neoplastic cells of oral squamous cell carci-
noma. They concluded that there was no evidence for a
role of EBV in the process of malignant transformation of
oral mucosa in immunocompetent individuals.
In the present work, immunoreactive EBV was detected
within the keratin pearls and in the central malignant cells
of squamous cell carcinoma. The pattern of staining was
nuclear, perinuclear, cytoplasmic as well as total cell reac-
tivity. This is in agreement with the findings of Greenspan
[20], Horiuchi et al [40], and Sandvej [41] who confirmed
the presence of EBV in a similar pattern of reaction.
Thus in this study, the presence of EBV proteins was dem-
onstrated in (73.6%) of all our studied cases while nega-
tive results were observed in the control specimens. This
result implies a possible direct relation between EBV
infection and epithelial dysplasia as well as squamous cell
carcinoma. Accordingly, our study appears to support the
view of others concerning the role of EBV in carcinogene-
sis [34,35].
In the present study, cancerous lesions of the oral mucosa
expressed EBV more prominent than did oral epithelial
dysplasia lesions. EBV expression was increased as tumor
differentiation was decreased.
In our study, we found that increased age did not enhance
EBV prevalence. Thus, the age does not seem to be a risk
factor for EBV infection. This result was in accordance
with other reports [35].
The relationship of proliferation markers with the grading
of dysplasia is uncertain, and the present investigation is
Table 3: Expression of EBV and Topo II∝ in relation to clinicopathological parameters in oral squamous cell carcinoma
Parameter Total n. EBV P-value Topo II-∝ P-value
Stage T 22
T1 8 29.24 ± 46.00 0.191 24.68 ± 5.96 0,038
T2 10 50.36 ± 30.71 26.38 ± 5.22
T3 4 45.48 ± 37.79 36.78 ± 9.39
N stage 22
N- 9 23.59 ± 23.71 0.009 23.04 ± 3.95 0.002
N+ 13 54.39 ± 26.62 30.84 ± 7.80
Differentiation 22
Well-diff. 10 36.09 ± 22.37 0.208 22.40 ± 3.19
Moderate-diff 8 41.15 ± 33.18 28.54 ± 4.84 0.000
Poorly-diff. 4 57.33 ± 38.91 39.00 ± 6.45Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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an attempt to remedy this. Recent immunohistochemical
studies have shown Topo II α to be a reliable indicator of
cell proliferation in tumors, such as breast, ovarian, and
bladder carcinomas, vulvar squamous lesions and oral
lichen planus [42-46]. Here, Topo II α was immunohisto-
chemically assessed in oral epithelial dysplasias, and car-
cinomas. Topo II α is an essential cellular enzyme that
functions in the segregation of newly replicated chromo-
some pairs, in chromosome condensation, and in altering
DNA superhelicity [47]. Because the expression of Topo II
α isoform increases during the late S phase, decreases at
the end of the M phase, and is dramatically reduced in the
G1/G0 phase of the cell cycle, [48] an anti-Topo II α anti-
body labels cells in the S, G2, and M phases of the cell
cycle [47]. The immunohistochemical method for the in
situ determination of Topo II α has been validated exten-
sively and shown to reflect closely the exact enzyme activ-
ity in formalin fixed paraffin wax embedded human
tissues [49]. On the contrary, techniques such as western
or northern blotting are averaging techniques and do not
assess the amount of Topo II α in one particular neoplas-
tic cell.
In general, the biological behavior of human malignan-
cies is influenced by two major biological features of can-
cer cells: abnormal proliferation and the potential to
invade and metastasise, which occasionally correlate with
each other [50].
In the present study, the intense positive nuclear immu-
nostaining expression of Topo II α was observed in the
basal and parabasal layers (stratum germnativum layer) of
nearly all normal oral epithelium regions while the gran-
ular and corneum cell layer showed less and variable
degree of positive nuclear immunostaining. This is in
agreement with the results of Liu et al., [51] who studied
the proliferative rate in intra oral sites and found that
basal cell layer and parabasal layer (stratum germnativum
cell layer) show high proliferative activity and no prolifer-
ative activity was seen above the parabasal layer (superfi-
cial layer). In this field Holden et al [52], Hellemans et al
[53] and Sandri et al [54] explained that the distribution
of Topo II α in normal human tissue was restricted to sites
known to harbor actively dividing cells. Also Truly et al
[55] found that Topo II α is detected in proliferating com-
partment of all normal tissues, as would be expected with
a cell division-specific role, as mitotic chromosomes seg-
regation and/or condensation.
Hotchin, Gandarillas and Watt [56] found that the prolif-
eration of keratinocyte is primarily restricted to the basal
layer. When keratinocytes divide, down-regulate cell sur-
face integrins to lose adhesiveness, leave the basal layer,
exit the cell cycle and undergo a program of terminal mat-
uration as they move through the suprabasal layers to the
tissue surface. During this journey, the keratinocytes
undergo a series of physiological and morphological
changes that terminate by production of dead, flattened
enucleated squames that are shed and replenished by dif-
ferentiating keratinocytes.
The intense nuclear and cytoplasmic immunoexpression
of Topo II α is observed in basal and parabasal layer in
studied epithelial tissues, although Earnshaw et al [57]
revealed that Topo II α has been shown to be a compo-
nent of two highly insoluble protein fractions from chro-
mosomes and nuclei, so these observation suggested that
Topo II α might be an integral structure of the nucleus.
The Topo II α in the studied tissues gives variable reaction
among different human oral tissues. The values of Topo II
α between studied cases cleared that it can be ordered the
oral tissues from highest to lowest immunoexpression as
follow lip, gingival inferior surface of tongue and hard
palate. The difference in immunoexpression of Topo II α
among different normal oral human tissues may be
explained by different opinion of many authors, Kellett,
Hume and Potten, [58], who studied the proliferation
rates and DNA synthesis in a continuous strip of epithe-
lium from the gingival sulcus to the ventral surface of the
tongue of mice and they found that the peak of prolifera-
tion and DNA synthesis in floor of mouth (lining
mucosa) is higher followed by attached gingiva then free
gingival epithelium. They concluded that there are various
aspects of the distribution of DNA synthesis and prolifer-
ation in relation to type and site of the studied cells.
The epithelial covering of the labial mucous membrane in
the present study showed highest nuclear immunoexpres-
sion of Topo II α among different other oral tissue. This is
coincided with Thomson et al [59] who studied the differ-
ence in mitotic index between human oral mucosa tissues
and found that there was a significant difference between
anatomical sites, with higher mitotic count observed in
buccal mucosa than mandibular gingiva. Meanwhile
Nagase et al [60] stated that the turnover time is the esti-
mated time needed to replace all cells in the epithelium
and is derived from knowledge of time taken for a certain
cell to divided and pass through the entire epithelium.
They added that the nonkeratinized epithelium turnover
faster than keratinized gingival epithelium and in general
the turnover time for skin needs 75 days, for cheek 25 days
and for gingiva 41–57 days. They concluded that there are
regional difference in a pattern of epithelial proliferation
and maturation associated with different turnover rates.
In the present study the keratinized epithelium of the gin-
gival tissues showed higher expression to Topo II α than
keratinized epithelium of hard palate in spite of that both
tissues are masticatory mucosa, this may be due to the dif-Diagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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ference in type of keratinization as Eckert, Crish and Rob-
inson [61] stated that in the oral cavity, Orthokeratinized
epithelium similar to that in skin is seen in the hard pal-
ate, whereas other regions are either parakeratinized (gin-
giva) and parakeratinized epithelium divide faster than
Orthokeratinized epithelium.
Also in the present study the epithelium of the lining
mucosa of the lip showed higher immunostaining than
that found in inferior surface of tongue this may be
explained by Burns et al [62] explained that there are sev-
eral possible explanations the most obvious explanation
relates to the possibility that gene expression may be reg-
ulated differently. And the regional differences in gene
expression could have many possible consequences. For
example, differential responsiveness to hormones and
growth factors and in their receptor, as there are differ-
ences in alpha adrenergic receptor number, might in turn
influence the time of appearance and activity of enzymes
and regulators involved in replication and differentiation.
In more details Philippe et al [63] suggested that the dif-
ferences in behavior of epithelial tissue from various
regions may reflect on site intrinsic characteristics to cells,
or cell clones rather than to external factor. They explained
that the disparate properties intrinsic to cells might due to
regionally different modes of cellular communication
including direct transmission of chemical messengers
between contiguous cells either by paracrine and auto-
crine mechanisms. They added that regional differences in
adipose tissue growth and distribution reflect intrinsic cel-
lular properties, rather than locational disparities or exter-
nal influences as blood or nerve supply, or ambient
temperature.
In the current work the epithelial lining of oral mucous
membrane of young group reveal intense immunoexpres-
sion to Topo II α than old group of different human oral
tissues population, they are highly significant P < 0.01.
This is in agreement with Stewart et al [64], who demon-
strated that the cells associated with aging, is decreased
metabolic efficiency (reduced growth rate), reduced off
spring production, and with increased chance of death.
Cardelli et al. [65] found that a progressive decrease of
proliferation rate was found during both physiologic
aging in vivo and induced aging in vitro.
In the other hand, Celenligil-Nazliel et al [66] found that
there is no significant difference was observed between
different age group with respect to proliferative activity in
healthy gingiva. Age-related changes in proliferative activ-
ity in human gingival epithelium are uncertain. All the tis-
sue sections contained positive staining cells for PCNA in
the gingival epithelium. Although PCNA expression was
observed both in the basal and suprabasal layers, it was
more prominent in the suprabasal layers. But in inflamed
gingiva was significantly higher in the older group. The
proliferative activity was found to be increased with aging.
As well as Evans, Galasko and Ward, [67] studied the
effect of age on growth of bone and found that the ability
of individual cells to divide and to perform specific syn-
thetic activities namely, total protein, osteocalcin, and
alkaline phosphatase synthesis, did not show any change
with increasing donor age. These results suggest that while
the ability of individual cells to divide and to perform is
unimpaired with increasing age, other subtler changes
may occur, leading to a decrease in the bone's osteogenic
capacity.
In our study, we also found that the Topo II-α index
increased with progression from OED to OSCC, presuma-
bly reflecting the increase in the number of cycling tumor
cells in invasive carcinomas.
Topo II-α was related to the clinicopathological parame-
ters and no significant correlation was found between
Topo II-α expression and patient's sex and tumor site. This
finding was in agreement with previous reports on oral
squamous cell carcinoma [68].
With regard to the age of OSCCs. High Topo II-α expres-
sion was more frequently detected among young age
group of OSCCs and the correlation of high Topo II-α
expression and age was statistically significant. In contrast,
Stathopoulos et al [69] found that there was no statisti-
cally significant correlation between them.
With regard to the degree of tumour differentiation, the
incidence of high Topo II-α immunopositivity was signif-
icantly greater in poorly differentiated SCCs. This strong
correlation is in agreement with one previous study in
head and neck squamous cell carcinomas [68] as well as
in other malignancies [49,52]. In malignant cells, overex-
pression of the Topo II-α protein might reflect not only
the proliferative advantage of these cells, but also qualita-
tive alterations caused by malignant transformation and
dedifferentiation. [47] In a recent study, treatment of the
hepatoma cell line Hep3B with retinoids(which can
induce cell differentiation) appeared to have a direct effect
on the Topo II-α gene promoter because it greatly reduced
both the steady state amount of mRNA and the transcrip-
tion rate of the Topo II-α gene[70]. This Topo II-α activity
increased as tumor differentiation was decreased and pri-
mary tumor size (T), regional lymph node metastasis (N),
and disease stage advanced, resulting in poor prognosis.
This finding was in agreement with Segawa et al [68] who
carried out a study on oral squamous cell carcinomas. On
the other hand, Stathopoulos et al [69] reported differ-
ently and stated that Topo II-α index of head and neckDiagnostic Pathology 2008, 3:45 http://www.diagnosticpathology.org/content/3/1/45
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squamous cell carcinoma did not correlate with clinico-
pathological parameters such as histologic type, lymph
node metastsasis, and tumor site. In addition, we found
that there was significant relationship between Topo II-α
and EBV expression in primary lesions was higher in cases
with lymph node metastasis than in those without lymph
node metastasis. As EBV expression increased, the Topo II-
α LI significantly increased. These findings coincided with
those of the present study. Therefore, these two enzyme
activities may be valuable diagnostic and prognostic indi-
ces in oral carcinoma.
As regards the two evaluated markers (Topo II-α and
EBV), they were not significantly related to each other in
OSCCs. However, increased expression of EBV correlated
significantly with elevated Topo II-α in OEDs. In addition
to, the expression of EBV was increased in the progression
from of OEDs to OSCCs, with elevation of Topo II-α LI.
These findings strongly indicate that EBV may contribute
to malignant transformation and tumor growth. This
result was in agreement with Shimakage [38].
Conclusion
1-Topo II α can be used as a valuable biomarker to esti-
mate proliferative activity in various sites of normal oral
mucous membrane. As there are direct relation between
the level of immunoexpression of it and the degree of pro-
liferation of examined tissue. This can give alert about the
proliferation state of normal cell or abnormal cell.
2-Increased expression of Topo II α expression in almost
all examined cases is related to the histological grade and
the stage of the disease, and denotes aggressive biological
behavior. Accordingly, Topo II α expression may be help-
ful in identifying those oral squamous cell carcinomas
with higher malignant potential, and could be used for
staging evaluation and predicting prognosis in premalig-
nancy and oral carcinomas.
3-Increased expression of EBV protein correlated with ele-
vated Topo II-∝ LI, indicating that EBV may contribute to
malignant transformation and tumor growth.
4-Age does not seem to be a risk factor for EBV infection.
Increased age did not enhance EBV prevalence.
Further studies are needed to reveal the role played by EBV
in carcinogensis of squamous cell carcinoma and to study
the impact of EBV infection on cellular immune response
to oral cancer. Furthermore, the etiologic role of EBV in
OSCC and OED needs to be examined in a prospective
follow-up study.
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